15
Apr
2008
Lanx: Series A $25M
Posted in CO Private: Lanx, Series A
Lanx (Broomfield) a medical device company developing and marketing surgical implants and biological products for spinal surgery closed a $25M Series A financing led by Chicago Growth Partners and also included co-investors Goldman Sachs and Oakwood Medical Investors. The Company currently markets 15 product lines of implants and associated instrumentation for spinal fusion surgery. Lanx [...]
11
Apr
2008
Amgen: Denosumab, Part III
Posted in CO Pub Rel: Amgen
CLSDF has been paying particular attention to the clinical development of Amgen’s (NASDAQ: AMGN) Denosumab, a monoclonal antibody that targets RANK Ligand, the essential mediator of osteoclasts – the cells that break down bone (Read Part I HERE and Part II HERE). Now, pivotal Phase III data shows Denosumab increased bone density at multiple skeletal [...]
10
Apr
2008
AspenBio Pharma and Novartis Ink License Deal
Posted in CO Pub Rel: Novartis, CO Public: Aspen BioPharma
AspenBio Pharma (NASDAQ: APPY) entered into a license agreement with Novartis Animal Health (NYSE: NVS) for the world-wide rights for the development and launch of AspenBio’s novel recombinant single-chain bovine products, BoviPure LH™ and BoviPure FSH™. The license agreement is generally for the term of the patents and the arrangement provides for a sharing of [...]
09
Apr
2008
Ceragenix: $1.5M Milestone Payment from Dr. Reddy’s
Posted in CO Pub Rel: Dr. Reddy's, CO Public: Ceragenix Pharma
Denver-based Ceragenix Pharmaceuticals (NASDAQ: CGXP.OB) a biopharmaceutical and medical device company focused on infectious disease and dermatology, announced that it received a $1.5M milestone payment pursuant to its exclusive distribution and supply agreement with Dr. Reddy’s Laboratories (NYSE: RDY), for the commercialization of EpiCeram®. Ceragenix has two base technology platforms – Ceragenins™ for treatment of [...]
08
Apr
2008
Back in February CLSDF highlighted Quark Pharmaceuticals as another private company headquartered outside of Colorado yet with a major presence in Colorado. The company announced the close of a $27M financing led by SBI Asset Management which may enable drug candidates in five clinical programs by 2H08. As a result of the financing clinical operations [...]
08
Apr
2008
It has been about a week since we last checked in on the progress of HB1001, yesterday the Colorado Bioscience bill that will inject over $26M into our ecosystem over the next five-years PASSED in the Senate!!! How exciting!!! Next stop for the legislation is to go back to the House for a final vote [...]
05
Apr
2008
Setting a pre-money valuation is always an interesting step in the funding process. I’ve seen potential deals quickly unwind as a result of an entrepreneur standing firm on an irrationally perceived valuation, or an unsophisticated angel investor(s) setting a seed round price that is misaligned with the venture community. It is always a terrible shame [...]
04
Apr
2008
The National Venture Capital Association released some interesting data highlighting the five fastest growing regions for attracting venture capital outside of Silicon Valley and New England. The analysis focused on the ten-year growth rates for regions across the country and ranked the fastest growing areas based upon the number of companies funded, excluding areas that [...]
03
Apr
2008
It is no secret that Replidyne (NASDAQ: RDYN) is highly focused upon architecting and executing a new strategic alliance, to replace the Forest Labs (NYSE: FRX) deal that unwound, in order to shepherd the commercialization efforts of Faropenem. A form 8K was filed with the SEC by the Louisville headquarters announcing a retention bonus has [...]
02
Apr
2008
Thom Cech, Ph.D.: Sweet Home Colorado!
Posted in People
Thom Cech who has been serving as the President of the Howard Hughes Medical Institute (HHMI) since 2000 announced that he will be stepping down in the spring of 2009 and returning to Colorado. Dr. Cech plans to resume his position as an HHMI investigator at the University of Colorado, where he has been a [...]
01
Apr
2008
Denver BioVentures emerged from stealth mode (though still no website) to announce the close of DBV Fund I, the rather impressively sized initial fund closed at $425M with their sights set exclusively on Colorado Bio. Patricia Tsanos, Ph.D., MBA who left Boston-based Adhesion Capital Partners last year wanted to spend more time at her 16,000 [...]
Life Science Deal Flow PARTNERS
-
